EXACT Sciences — Q4 2024 Earnings Presentation
19 slides from EXACT Sciences's earnings presentation, Feb 19, 2025
Slide 1: Fourth-quarter 2024 earnings call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Fourth-quarter 2024 earnings call February 19, 2025 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Global leader in advanced cancer diagnostics with a differentiated platform
Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform OUR PEOPLE OUR IMPACT & SCALE OUR CAPABILITIES 7,000+ 4.6M Proprietary scientific platform detects cancer earlier and accurately team members test results in 2024 1,400+ $2.76B Powerful commercial engine,
Slide 4: Core revenue grew 11% in 4Q24
Core revenue grew 11% in 4Q24 Core revenue Screening revenue Precision Oncology revenue $715M $645M +11% $553M $487M +14% $160M $161M +0.4% 4Q23 4Q24 4Q23 4Q24 4Q23 4Q24 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and re
Slide 5: Profitability continued to improve in Q4, allowing investment in new product launches
Profitability continued to improve in Q4, allowing investment in the launch of new products Adjusted EBITDA Adjusted EBITDA margin $75M 11% +52% ~300 bps $50M 8% 4Q23 4Q24 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 6: 2024 was another year of profitable revenue growth
2024 was another year of profitable revenue growth Core revenue Adjusted EBITDA Free cash flow Adjusted EBITDA margin $2.752B $323M $2.486B +11% 12% +48% $75M ~300 bps $219M 9% +133% $32M 2023 2024 2023 2024 2023 2024 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for
Slide 7: 2025 guidance reflects double-digit growth and continued profit expansion
2025 guidance reflects double-digit growth and continued profit expansion $ ∆ at % ∆ at 2024 2025 midpoint midpoint Total revenue $2.759B $3.025 – 3.085B +$296M +11% Screening $2.104B $2.350 - 2.390B +$266M +13% Precision Oncology $655M $675 - 695M +$30M +5% Adj. EBITDA $323M $410 - 440M +$102M +31%
Slide 8: Cologuard is driving sustainable growth
Cologuard® is driving sustainable growth Increasing Cologuard rescreen rates Engaging highest potential ordering providers Closing care gaps with payers and health systems Making Cologuard PlusTM the new standard of care Targeting younger people through new ads EXACT SCIENCES 8
Slide 9: Expanding our global presence and launching new tests onto our oncology platform
Expanding our global presence and launching new tests onto our oncology platform Patients tested in 2024 with Oncotype DX® Expanding Oncotype DX impact internationally Improving customer experience with ExactNexus Bringing Oncodetect to patients and providers Source: Exact Sciences internal data EXA
Slide 10: Progress with Oncodetect and upcoming milestones
Oncodetect uses unique science to predict and detect cancer relapses earlier Progress Progress Progress with with with Oncodetect Oncodetect multi-cancer early andupcoming and upcoming detection milestones and milestones upcoming milestones A positive Oncodetect Oncodetect patient is detects relapse
Slide 11: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 11
Slide 12: EXACT SCIENCES
EXACT SCIENCES 12
Slide 13: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Revenue $ 713,424 $ 646,885 $ 2,758,867 $ 2,499,766 C
Slide 14: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 600,889 $ 605,378 Marketable securities 437,137 172,266 Accounts receivable, net 248,968 203,623 Inv
Slide 15: U.S. GAAP to Non-GAAP Reconciliation: Core Revenue
EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Core Revenue (Unaudited) (Amounts in thousands) GAAP Three Months Ended December 31, 2024 2023 % Change Screening $ 552,563 $ 486,706 14 % Precision Oncology 160,861 160,179 — % Total $ 713,424 $ 646,885 10 % Non-GAAP Three Months Ended
Slide 16: U.S. GAAP to Non-GAAP Reconciliation: Adjusted EBITDA
EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Adjusted EBITDA (Unaudited) (Amounts in thousands) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net loss $ (864,585) $ (49,766) $ (1,028,857) $ (204,149) Interest expense (1) 9,577 7,865 27,016 19
Slide 17: U.S. GAAP to Non-GAAP Reconciliations
EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliations U.S. GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended December 31, 2024 Research & General & Development Sales & Marketing Administrative Loss from Income Tax Benefit Gross Profit Expenses Expenses Expens
Slide 18: U.S. GAAP to Non-GAAP Reconciliation
EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation U.S. GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended December 31, 2023 Research & General & Development Sales & Marketing Administrative Loss from Income Tax Benefit Gross Profit Expenses Expenses Expense
Slide 19: U.S. GAAP to Non-GAAP Reconciliation: Operating Cash Flow to Free Cash Flow
EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Operating Cash Flow to Free Cash Flow (Unaudited) (Amounts in thousands) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net cash provided by operating activities $ 47,063 $ 69,549 $ 210,536 $ 156,11